TRAF7 in signaling and disease: emerging mechanisms and clinical implications

Our plain-English summary of TRAF7 in signaling and disease: emerging mechanisms and clinical implications, by A. Orock, J.A. Zuccato, K. Phan, et al (Molecular Medicine, 2025).

The study

• Authors: A. Orock, J.A. Zuccato, K. Phan, Y. Liu, J. Ihuoma, S. Tavakol, A.V. Tsytsykova, E.N. Tsitsikov, S. Tarantini, A.C. Johnson, I.F. Dunn
• Journal: Molecular Medicine
• Published: 2025;32(1):4
• Type of article: Review
• Cited by: 2 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Tumor necrosis factor receptor-associated factors (TRAFs) are a family of 7 signaling proteins that have regulatory roles in multiple fundamental cellular processes, including immunity, inflammation, apoptosis, permeability, and cell proliferation. TRAF7 is the most recently described with unique features distinguishing it from other TRAFs. It is an E3 ubiquitin ligase that activates MEKK3 and KLF2/4 signaling, inhibits MEK1/2 and c-Myb along with an NF-κβ-modulator, and stabilizes VE-cadherins in cell junctions. Germline mutations in TRAF7 lead to developmental delays and the dysmorphic features associated with TRAF7 syndrome. Somatic TRAF7 mutations are associated with subsets of meningiomas, mesotheliomas, and perineuriomas. Additionally, TRAF7 altered expression is associated with poorer prognoses in hepatocellular carcinoma, breast cancer, and prostate cancer. This review comprehensively describes the physiological roles of TRAF7 and the pathophysiology of clinical conditions with TRAF7 alterations. We highlight important directions for future work to improve our understanding of the mechanisms underlying TRAF7 related disease, identify prognostic biomarkers that help guide clinical decision making, and potentially identify novel therapeutic targets to expand our treatment options for these patients.

© 2025. The Author(s).

In plain English

This article was a narrative review, not a new study. The authors summarized published laboratory, animal and patient research on TRAF7, a cell-signaling protein, and reported no new data. It did not discuss asbestos. The review described TRAF7 as an E3 ubiquitin ligase with a regulatory role in pathways for immune and inflammatory function, cell growth, cell survival and endothelial integrity. Citing other studies, it reported that germline TRAF7 mutations had been found in at least 70 patients with a developmental disorder known as TRAF7 syndrome, and that acquired (somatic) TRAF7 mutations were found in 25% of meningiomas. On mesothelioma, the review cited earlier work reporting TRAF7 mutations in 90% of well-differentiated papillary peritoneal mesothelial tumors. It stated that well-differentiated papillary mesothelioma, which follows an indolent course, is genetically defined by TRAF7 or CDC42 alterations that set it apart from malignant mesothelioma. The authors concluded that TRAF7 plays an oncogene role in some conditions and a tumor suppressor role in others. They named building animal models that reflect human disease as a key challenge.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published research on TRAF7 (no new data generated)
• Who was studied: No study population. The review drew on previously published cell, animal (mouse, rat, zebrafish) and patient studies.
• Exposure: No asbestos or fiber exposure was studied. The subject was TRAF7 gene mutations (germline and somatic) and altered TRAF7 expression.
• Main results:
  • The review described TRAF7 as an E3 ubiquitin ligase with a regulatory role in signaling for immune and inflammatory function, cell growth, survival and endothelial integrity.
  • Citing earlier work, the review reported germline TRAF7 mutations in at least 70 patients with a developmental disorder (TRAF7 syndrome).
  • Citing earlier studies, the review reported that TRAF7 mutations are the second most common alteration in meningioma, found in 25% of tumors.
  • Citing earlier studies (Offin et al. 2024; Stevers et al. 2019), the review reported cohorts in which 90% of well-differentiated papillary peritoneal mesothelial tumors carried TRAF7 mutations.
  • The review stated that well-differentiated papillary mesothelioma is genetically defined by TRAF7 or CDC42 alterations, which distinguish it from malignant mesothelioma. It described the well-differentiated papillary form as following an indolent course.
  • The review described TRAF7 as a biomarker for adenomatoid tumors of the genital tract, which are benign serosal mesothelial tumors.
  • Citing earlier studies, the review described TRAF7 overexpression in hepatocellular carcinoma as associated with larger and higher-grade tumors and poorer prognosis.
• The authors' conclusion: The authors concluded that TRAF7 has a wide range of functions, acting as an oncogene in some conditions and a tumor suppressor in others, and that further work is needed on the mechanisms involved.
• Limitations the authors state:
  • The authors stated that the functions of TRAF7 are incompletely characterized.
  • The authors stated that a key challenge is developing animal models that accurately reflect human TRAF7-related conditions.

Topics

Medical terms in this study, explained in our Lexicon: Necrosis, Inflammation, Apoptosis, Germline Mutation, Mesothelioma, Carcinoma, Biomarker.

Related studies

• Well-differentiated papillary mesothelioma of the peritoneum is genetically defined by mutually exclusive mutations in TRAF7 and CDC42 — M. Stevers, J.T. Rabban, et al. (2019)
• TRAF7 mutations and immunohistochemical study of uterine adenomatoid tumor compared with malignant mesothelioma — H. Itami, T. Fujii, et al. (2021)
• Adenomatoid tumors of the male and female genital tract are defined by TRAF7 mutations that drive aberrant NF-kB pathway activation — B. Goode, N.M. Joseph, et al. (2018)
• The Emerging Role of the Hippo Pathway in Lung Cancers: Clinical Implications — S.L. Teoh, S. Das (2017)
• Aquaporins in lung health and disease: Emerging roles, regulation, and clinical implications — E. Yadav, N. Yadav, et al. (2020)
• Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome — J.H. Cho, A.Y. Oh, et al. (2018)

Browse return to medical research.